CStone Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:PH4 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Dec 24Sell€42,309Jianxin YangIndividual149,500€0.28
27 Dec 24Sell€43,548Jianxin YangIndividual150,000€0.29
25 Oct 24Buy€222,709Zhengguo HuIndividual921,000€0.24
18 Oct 24Buy€180,695Jianxin YangIndividual886,500€0.20
17 Sep 24Sell€110,418Suzhou Oriza Holdings Co., Ltd.Company590,500€0.19
21 Jun 24Buy€21,003Jianxin YangIndividual160,500€0.13
20 Jun 24Buy€15,706Jianxin YangIndividual122,500€0.13
19 Jun 24Buy€25,343Jianxin YangIndividual200,000€0.13
18 Jun 24Buy€19,140Jianxin YangIndividual150,000€0.13
17 Jun 24Buy€12,716Jianxin YangIndividual100,000€0.13
07 Jun 24Buy€48,499Jianxin YangIndividual350,000€0.14
06 Jun 24Buy€28,357Jianxin YangIndividual200,000€0.14
05 Jun 24Buy€14,669Jianxin YangIndividual100,000€0.15
24 Apr 24Buy€6,151Jianxin YangIndividual58,500€0.11
23 Apr 24Buy€5,009Jianxin YangIndividual50,000€0.10
22 Apr 24Buy€4,979Jianxin YangIndividual50,000€0.10
19 Apr 24Buy€134,087Jianxin YangIndividual1,324,000€0.10
19 Apr 24Buy€65,782Hitchner III WaltonIndividual645,500€0.10
18 Apr 24Buy€11,698Jianxin YangIndividual114,500€0.10
18 Apr 24Buy€22,601Hitchner III WaltonIndividual214,000€0.11
17 Apr 24Buy€18,083Jianxin YangIndividual176,500€0.10
17 Apr 24Buy€16,534Hitchner III WaltonIndividual160,000€0.10
16 Apr 24Buy€20,062Jianxin YangIndividual200,000€0.10
16 Apr 24Buy€26,599Hitchner III WaltonIndividual264,000€0.10
15 Apr 24Buy€18,396Jianxin YangIndividual178,500€0.10
15 Apr 24Buy€33,476Hitchner III WaltonIndividual319,500€0.10
12 Apr 24Buy€17,974Jianxin YangIndividual171,500€0.10
12 Apr 24Buy€15,978Hitchner III WaltonIndividual152,000€0.11
12 Apr 24Buy€54,504Hitchner III WaltonIndividual518,500€0.11
11 Apr 24Buy€12,580Hitchner III WaltonIndividual121,500€0.10
10 Apr 24Buy€9,383Hitchner III WaltonIndividual90,500€0.10
09 Apr 24Buy€25,766Hitchner III WaltonIndividual252,500€0.10

Insider Trading Volume

Insider Buying: PH4 insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of PH4?
Owner TypeNumber of SharesOwnership Percentage
Institutions9,858,2610.772%
Individual Insiders26,582,7412.08%
Public Companies115,928,8039.08%
VC/PE Firms499,972,20839.2%
General Public624,304,12848.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 10 shareholders own 51.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
23%
6 Dimensions Capital Limited
293,381,444€106.7m0%37.4%
11.2%
Boyu Capital Group Management Ltd.
142,560,448€51.8m0%5.52%
9.08%
Pfizer Inc.
115,928,803€42.2m0%no data
5.02%
Suzhou Oriza Holdings Co., Ltd.
64,030,316€23.3m0%2.16%
1.28%
Jianxin Yang
16,304,256€5.9m0.15%no data
0.76%
Franklin Resources, Inc.
9,741,761€3.5m18.6%no data
0.53%
Xiao Yanni
6,760,000€2.5m0%no data
0.2%
Hitchner III Walton
2,597,485€944.6k0.62%no data
0.072%
Zhengguo Hu
921,000€334.9k0%no data
0.0091%
State Street Global Advisors, Inc.
116,500€42.4k-5.28%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 12:28
End of Day Share Price 2025/02/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CStone Pharmaceuticals is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Ling WangJ.P. Morgan
Sean WuMorgan Stanley